APC 366
目录号 : GC16688A mast cell tryptase inhibitor
Cas No.:158921-85-8
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
APC 366 is a selective and competitive inhibitor of tryptase [1, 2, 3]. After about 4 h of incubation with human tryptase, APC 366 showed an inhibitory potential with a Ki value of 530 nM and an IC50 value of 1400 ± 240 nM [3].
Tryptase is a mast cell serine protease. It had been implicated in the allergic asthma pathophysiology [2].
It seemed that actions of tryptase were dependent on an intact catalytic site. APC 366 inhibited DNA synthesis and the proliferation of the smooth muscle cell (SMC) induced by tryptase. In this study, thymidine incorporation was reduced by APC 366 by 79%. Heating to inactivate enzymatic activity also abolished the ability of tryptase to stimulate SMC proliferation and DNA synthesis [4].
In urine in the control pigs, the concentration of histamine was immediately elevated after allergen challenge. But treatment with APC 366 markedly decreased this release [5]. In vivo in a sheep model, administration with APC 366 decreased allergen-induced early and late-phase bronchoconstriction and hyperresponsiveness [4]. In allergic sheep, APC 366 was administered by aerosol in all experiments. In vehicle control trials, antigen challenge caused peak early and late increases in specific lung resistance with values of 259 ± 30% and 183 ± 27% over baseline, respectively. 0.5 h before, 4 h after and 24 h after antigen challenge, treatment with APC 366 at 9 mg/3 ml H2O slightly decreased the peak early response (194 ± 41%) and significantly inhibited the late response (38 ± 6%, p < 0.05) [2].
References:
[1]. Krishna MT, Chauhan A, Little L, et al. Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma. Journal of Allergy and Clinical Immunology, 2001, 107(6): 1039-1045.
[2]. Clark JM, Abraham WM, Fishman CE, et al. Tryptase inhibitors block allergen-induced airway and inflammatory responses in allergic sheep. American journal of respiratory and critical care medicine, 1995, 152(6): 2076-2083.
[3]. Hallgren J, Estrada S, Karlson U, et al. Heparin antagonists are potent inhibitors of mast cell tryptase. Biochemistry, 2001, 40(24): 7342-7349.
[4]. Berger P, Perng DW, Thabrew H, et al. Tryptase and agonists of PAR-2 induce the proliferation of human airway smooth muscle cells. Journal of Applied Physiology, 2001, 91(3): 1372-1379.
[5]. Sylvin H, Dahlbck M, Van Der Ploeg I, et al. The tryptase inhibitor APC-366 reduces the acute airway response to allergen in pigs sensitized to Ascaris suum. Clinical & Experimental Allergy, 2002, 32(6): 967-971.
Cas No. | 158921-85-8 | SDF | |
化学名 | (S)-1-((S)-5-guanidino-2-(1-hydroxy-2-naphthamido)pentanoyl)pyrrolidine-2-carboxamide | ||
Canonical SMILES | O=C(C1=C(O)C2=CC=CC=C2C=C1)N[C@@H](CCCNC(N)=N)C(N3[C@H](C(N)=O)CCC3)=O | ||
分子式 | C22H28N6O4 | 分子量 | 440.5 |
溶解度 | Soluble to 5 mg/ml in 20% ethanol / Water | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.2701 mL | 11.3507 mL | 22.7015 mL |
5 mM | 0.454 mL | 2.2701 mL | 4.5403 mL |
10 mM | 0.227 mL | 1.1351 mL | 2.2701 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。